Annabel Helga Sophie Alig

5PUBLICATIONS
39CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 05, 2026
Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.

Julius Keyl, René Hosch, Fabian Hörst

|Jul 30, 2025
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.

Alexej Ballhausen, Susanna Swoboda, David Horst

|Apr 05, 2023
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).

Arndt Stahler, Beeke Hoppe, Il-Kang Na

|Feb 15, 2022
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.

Annabel H S Alig, Volker Heinemann, Michael Geissler

|Jul 26, 2021
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).

Arndt Stahler, Volker Heinemann, Julian Walter Holch

Pageof 1

Frequent Collaborators

5 joint publications

Sebastian Stintzing

4 joint publications

Dominik Paul Modest

4 joint publications

Arndt Stahler

3 joint publications

Volker Heinemann